BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Your Company//NONSGML v1.0//EN
BEGIN:VEVENT
SUMMARY:Symposium on Emerging Resistance to Novel Tuberculosis Drugs
DESCRIPTION:See 2024 Presentations here For the first time in 50 years, novel antimycobacterial agents have been developed, allowing major leaps forward in tuberculosis (TB) treatment. Recent clinical trials showcase remarkable advances in treating multidrug-resistant TB (MDR-TB) with the introduction of new all-oral regimens incorporating drugs such as Bedaquiline, nitroimidazoles, and repurposed agents. These drugs also play crucial roles in experimental regimens for ultra-short courses in drug-susceptible TB, TB infection treatment, and universal TB regimens (e.g., PAN-TB), showing promise in shortening treatment duration and improving outcomes across the TB spectrum. However, with global implementation of these new regimens, there has been a growing […]
LOCATION:
STATUS:CONFIRMED
SEQUENCE:0
UID:6896149584943@sshiftb.org
BEGIN:VALARM
TRIGGER:-PT10M
DESCRIPTION:Reminder
ACTION:DISPLAY
END:VALARM
END:VEVENT
END:VCALENDAR